Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 219Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 3Diovan

02 6Diovan Group

03 2Diovan/Co-Diovan

04 2Entresto

05 6Exforge

06 5Exforge Group

PharmaCompass

01

Brand Name : Exforge Group

Hydrochlorothiazide, Valsartan

arrow
ChemOutsourcing
Not Confirmed

Brand Name : Exforge Group

arrow
ChemOutsourcing
Not Confirmed

Hydrochlorothiazide, Valsartan

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2020 Revenue in Millions : 980

2019 Revenue in Millions : 1,025

Growth (%) : -4

blank

02

Brand Name : Diovan Group

Hydrochlorothiazide, Valsartan

arrow
ChemOutsourcing
Not Confirmed

Brand Name : Diovan Group

arrow
ChemOutsourcing
Not Confirmed

Hydrochlorothiazide, Valsartan

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2020 Revenue in Millions : 1,003

2019 Revenue in Millions : 1,064

Growth (%) : -6

blank

03

Brand Name : Entresto

Hydrochlorothiazide, Valsartan

arrow
ChemOutsourcing
Not Confirmed

Brand Name : Entresto

arrow
ChemOutsourcing
Not Confirmed

Hydrochlorothiazide, Valsartan

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2020 Revenue in Millions : 2,497

2019 Revenue in Millions : 1,726

Growth (%) : 45

blank

04

Brand Name : Diovan Group

Hydrochlorothiazide, Valsartan

arrow
ChemOutsourcing
Not Confirmed

Brand Name : Diovan Group

arrow
ChemOutsourcing
Not Confirmed

Hydrochlorothiazide, Valsartan

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2021 Revenue in Millions : 773

2020 Revenue in Millions : 1,003

Growth (%) : -23

blank

05

Brand Name : Exforge Group

Hydrochlorothiazide, Valsartan

arrow
ChemOutsourcing
Not Confirmed

Brand Name : Exforge Group

arrow
ChemOutsourcing
Not Confirmed

Hydrochlorothiazide, Valsartan

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2021 Revenue in Millions : 901

2020 Revenue in Millions : 980

Growth (%) : -8

blank

06

Brand Name : Diovan Group

Hydrochlorothiazide, Valsartan

arrow
ChemOutsourcing
Not Confirmed

Brand Name : Diovan Group

arrow
ChemOutsourcing
Not Confirmed

Hydrochlorothiazide, Valsartan

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2022 Revenue in Millions : 652

2021 Revenue in Millions : 773

Growth (%) : -16

blank

07

Brand Name : Exforge Group

Hydrochlorothiazide, Valsartan

arrow
ChemOutsourcing
Not Confirmed

Brand Name : Exforge Group

arrow
ChemOutsourcing
Not Confirmed

Hydrochlorothiazide, Valsartan

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2022 Revenue in Millions : 743

2021 Revenue in Millions : 901

Growth (%) : -18

blank

08

Brand Name : Exforge Group

Hydrochlorothiazide, Valsartan

arrow
ChemOutsourcing
Not Confirmed

Brand Name : Exforge Group

arrow
ChemOutsourcing
Not Confirmed

Hydrochlorothiazide, Valsartan

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2023 Revenue in Millions : 713

2022 Revenue in Millions : 743

Growth (%) : -4

blank

09

Brand Name : Diovan Group

Hydrochlorothiazide, Valsartan

arrow
ChemOutsourcing
Not Confirmed

Brand Name : Diovan Group

arrow
ChemOutsourcing
Not Confirmed

Hydrochlorothiazide, Valsartan

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2023 Revenue in Millions : 613

2022 Revenue in Millions : 652

Growth (%) : -6

blank

10

Brand Name : Diovan Group

Hydrochlorothiazide, Valsartan

arrow
ChemOutsourcing
Not Confirmed

Brand Name : Diovan Group

arrow
ChemOutsourcing
Not Confirmed

Hydrochlorothiazide, Valsartan

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2024 Revenue in Millions : 590

2023 Revenue in Millions : 613

Growth (%) : -4

blank